<?xml version='1.0' encoding='utf-8'?>
<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
  <article article-type="research-article" xml:lang="en" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
        <journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
        <journal-id journal-id-type="pmc-domain-id">1761</journal-id>
        <journal-id journal-id-type="pmc-domain">tp</journal-id>
        <journal-title-group>
          <journal-title>Translational Psychiatry</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2158-3188</issn>
        <publisher>
          <publisher-name>Nature Publishing Group</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8531440</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8531440.1</article-id>
        <article-id pub-id-type="pmcaid">8531440</article-id>
        <article-id pub-id-type="pmcaiid">8531440</article-id>
        <article-id pub-id-type="pmid">34675189</article-id>
        <article-id pub-id-type="doi">10.1038/s41398-021-01621-2</article-id>
        <article-id pub-id-type="publisher-id">1621</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Methylphenidate modulates interactions of anxiety with cognition</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9199-7974</contrib-id>
            <name name-style="western">
              <surname>Gaillard</surname>
              <given-names initials="C">C.</given-names>
            </name>
            <address>
              <email>claudie.gaillard@nih.gov</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lago</surname>
              <given-names initials="TR">T. R.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gorka</surname>
              <given-names initials="AX">A. X.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8565-1544</contrib-id>
            <name name-style="western">
              <surname>Balderston</surname>
              <given-names initials="NL">N. L.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Fuchs</surname>
              <given-names initials="BA">B. A.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Reynolds</surname>
              <given-names initials="RC">R. C.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Grillon</surname>
              <given-names initials="C">C.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ernst</surname>
              <given-names initials="M">M.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <aff id="Aff1">
            <label>1</label>
            <institution-wrap>
              <institution-id institution-id-type="GRID">grid.416868.5</institution-id>
              <institution-id institution-id-type="ISNI">0000 0004 0464 0574</institution-id>
              <institution>Section on Neurobiology of Fear and Anxiety, </institution>
              <institution>National Institute of Mental Health, </institution>
            </institution-wrap>Bethesda, MD USA </aff>
          <aff id="Aff2">
            <label>2</label>
            <institution-wrap>
              <institution-id institution-id-type="GRID">grid.189504.1</institution-id>
              <institution-id institution-id-type="ISNI">0000 0004 1936 7558</institution-id>
              <institution>Department of Psychiatry, </institution>
              <institution>Boston University School of Medicine, </institution>
            </institution-wrap>Boston, MA USA </aff>
          <aff id="Aff3">
            <label>3</label>
            <institution-wrap>
              <institution-id institution-id-type="GRID">grid.25879.31</institution-id>
              <institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id>
              <institution>Center for Neuromodulation in Depression and Stress, Department of Psychiatry, </institution>
              <institution>University of Pennsylvania, </institution>
            </institution-wrap>Philadelphia, PA USA </aff>
          <aff id="Aff4">
            <label>4</label>
            <institution-wrap>
              <institution-id institution-id-type="GRID">grid.29857.31</institution-id>
              <institution-id institution-id-type="ISNI">0000 0001 2097 4281</institution-id>
              <institution>Department of Nutritional Sciences, </institution>
              <institution>The Pennsylvania State University, </institution>
            </institution-wrap>University Park, PA USA </aff>
          <aff id="Aff5">
            <label>5</label>
            <institution-wrap>
              <institution-id institution-id-type="GRID">grid.416868.5</institution-id>
              <institution-id institution-id-type="ISNI">0000 0004 0464 0574</institution-id>
              <institution>Scientific and Statistical Computing Core, </institution>
              <institution>National Institute of Mental Health, </institution>
            </institution-wrap>Bethesda, MD USA </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>21</day>
          <month>10</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="collection">
          <year>2021</year>
        </pub-date>
        <volume>11</volume>
        <issue-id pub-id-type="pmc-issue-id">372443</issue-id>
        <elocation-id>544</elocation-id>
        <self-uri content-type="pmc-pdf" ns0:href="41398_2021_Article_1621.pdf" />
        <abstract id="Abs1">
          <p id="Par1">While a large body of literature documents the impairing effect of anxiety on cognition, performing a demanding task was shown to be effective in reducing anxiety. Here we explored the mechanisms of this anxiolytic effect by examining how a pharmacological challenge designed to improve attentional processes influences the interplay between the neural networks engaged during anxiety and cognition. Using a double-blind between-subject design, we pharmacologically manipulated working memory (WM) using a single oral dose of 20 mg methylphenidate (MPH, cognitive enhancer) or placebo. Fifty healthy adults (25/drug group) performed two runs of a WM <italic toggle="yes">N</italic>-back task in a 3 T magnetic resonance imaging scanner. This task comprised a low (1-Back) and high (3-Back) WM load, which were performed in two contexts, safety or threat of shocks (induced-anxiety). Analyses revealed that (1) WM accuracy was overall improved by MPH and (2) MPH (vs. placebo) strengthened the engagement of regions within the fronto-parietal control network (FPCN) and reduced the default mode network (DMN) deactivation. These MPH effects predominated in the most difficult context, i.e., threat condition, first run (novelty of the task), and 3-Back task. The facilitation of neural activation can be interpreted as an expansion of cognitive resources, which could foster both the representation and integration of anxiety-provoking stimuli as well as the top–down regulatory processes to protect against the detrimental effect of anxiety. This mechanism might establish an optimal balance between FPCN (cognitive processing) and DMN (emotion regulation) recruitment.</p>
        </abstract>
        <kwd-group kwd-group-type="npg-subject">
          <title>Subject terms</title>
          <kwd>Psychiatric disorders</kwd>
          <kwd>Human behaviour</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000025</institution-id>
                <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
              </institution-wrap>
            </funding-source>
            <award-id>ZIAMH002798</award-id>
            <award-id>ZIAMH002798</award-id>
            <award-id>ZIAMH002798</award-id>
            <award-id>ZIAMH002798</award-id>
            <award-id>ZIAMH002798</award-id>
            <award-id>ZIAMH002798</award-id>
            <award-id>ZIAMH002798</award-id>
            <award-id>ZIAMH002798</award-id>
            <principal-award-recipient>
              <name name-style="western">
                <surname>Gaillard</surname>
                <given-names>C.</given-names>
              </name>
              <name name-style="western">
                <surname>Lago</surname>
                <given-names>T. R.</given-names>
              </name>
              <name name-style="western">
                <surname>Gorka</surname>
                <given-names>A. X.</given-names>
              </name>
              <name name-style="western">
                <surname>Balderston</surname>
                <given-names>N. L.</given-names>
              </name>
              <name name-style="western">
                <surname>Fuchs</surname>
                <given-names>B. A.</given-names>
              </name>
              <name name-style="western">
                <surname>Reynolds</surname>
                <given-names>R. C.</given-names>
              </name>
              <name name-style="western">
                <surname>Grillon</surname>
                <given-names>C.</given-names>
              </name>
              <name name-style="western">
                <surname>Ernst</surname>
                <given-names>M.</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-license-ref</meta-name>
            <meta-value>CC BY</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© The Author(s) 2021</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1" sec-type="introduction">
        <title>Introduction</title>
        <p id="Par2">While a large body of literature documents the impairing effect of anxiety on cognition [for reviews, see [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR4">4</xref>], performing a demanding task was shown to be effective in reducing anxiety [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR10">10</xref>]. This neuroimaging study examines potential neural mechanisms underlying this effect that could be exploited in the treatment of anxiety. To this aim, a pharmacological manipulation of cognitive function using a cognitive enhancer (methylphenidate (MPH)) was designed to investigate the interaction of induced-anxiety with performance on a working memory (WM) task.</p>
        <p id="Par3">Heuristic models of anxiety provide strong anchors for the formulation of hypotheses in which cognitive mechanisms are prominent [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. For example, the famous revised model of WM elaborated by Baddeley et al. [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] provides a mechanistic framework based on cognitive resources to account for anxiety. Most importantly, this model communicates the principle of limited cognitive capacity, which, when insufficient, results in behavioral perturbations [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Indeed, finite cognitive capacity leads to competition between processes, favoring the processing of the most biologically salient behavior [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. In contrast to this well-recognized theory, a recent behavioral study conducted in our laboratory suggested that, in fact, cognitive capacity may not be finite [<xref ref-type="bibr" rid="CR16">16</xref>]. This behavioral study was designed to test interactions of anxiety and cognition, as each was manipulated separately. MPH, a cognitive enhancer (20 mg PO) was expected to facilitate cognitive performance (<italic toggle="yes">N</italic>-Back WM) through the prioritization of cognitive processes and at the expense of the processing of anxiety. Anxiety was induced by unpredictable threat of shock. Compared to placebo (PLA), MPH administration alleviated the impairing effect of induced-anxiety on WM accuracy at the highest cognitive load (i.e., 3-Back task). At the same time, MPH was associated with stronger physiological responses (startle reflex) to anxiety (threat of shock). These findings suggested that cognitive resources could be used to both foster the engagement of cognitive capacity and to process anxiety-provoking stimuli and associated defensive responses. In the present study, we wished to test this hypothesis against the classical limited resources model, at the neural level.</p>
        <p id="Par4">Two neural networks play an essential role regarding the impact of cognition on anxiety, the fronto-parietal control network (FPCN) and the default mode network (DMN). Cognitive function, such as WM, activates the FPCN (task-positive network) and deactivates the DMN (task-negative network) [for a review, see [<xref ref-type="bibr" rid="CR17">17</xref>]]. Anxiety alters both the FCPN and the DMN, in ways that depend on the context [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], for reviews, see [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The most common effects of anxiety on neural networks, evidenced by resting-state neuroimaging studies, are of two types: (1) an impaired functional connectivity of both the FPCN (responsible for processes of attention, control, supervision) and DMN (responsible for self-referential processes), and (2) an increased functional connectivity of the salience network (responsible for coding biological significance of stimuli) and the bottom–up attention network (i.e., ventral attention network, responsible for stimulus-driven attention processes) [for a review, see [<xref ref-type="bibr" rid="CR21">21</xref>]]. Additionally, anxiety is associated with a hypoconnectivity between the affective network and both the FPCN and DMN, as well as a decoupling between the FPCN and the DMN [for a meta-analytic review, see [<xref ref-type="bibr" rid="CR20">20</xref>]]. Here we propose a theoretical framework based on a relative functional balance between FPCN and DMN. This framework provides three possible alternate mechanisms underlying the relation between cognitive enhancement and anxiety reduction (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>): (A) MPH increases the dissociation between the engagement of the FPCN and DMN, as reflected in the combination of (i) stronger activation of FPCN regions (task-positive network), which favors cognitive performance, and (ii) steeper deactivation of DMN regions (task-negative network), which prevents interference from irrelevant stimuli such as self-referential thoughts (worry) [for a review, see [<xref ref-type="bibr" rid="CR20">20</xref>]]. (B) MPH permits a redistribution of cognitive resources as indicated by lower resource allocation to the FPCN (weaker activation), which signals MPH-related increased efficiency of the executive control system [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], leaving more resources to process and inhibit anxiety (i.e., increased DMN activation). (C) MPH expands overall neural resources as reflected by stronger activation of both the FPCN (i.e., better cognitive performance and inhibition of interference from non-relevant stimuli) and the DMN (i.e., processing of anxiety without interfering with cognitive performance and allowing regulatory control of anxiety) [<xref ref-type="bibr" rid="CR16">16</xref>].<fig id="Fig1" position="float" orientation="portrait">
            <label>Fig. 1</label>
            <caption>
              <title>Schematics of the three predictions underpinning MPH-mediated cognitive enhancement.</title>
              <p>
                <bold>A</bold> MPH-driven increase in the dissociation between the engagement of the FPCN and DMN as reflected by (i) stronger activation of fronto-parietal control network (FPCN) regions (task-positive network), which favors cognitive performance and (ii) steeper deactivation of default mode network (DMN) regions (task-negative network), which prevents interference from irrelevant stimuli such as anxiety-related signals. <bold>B</bold> MPH-driven redistribution of cognitive resources as indicated by lower resource allocation to the FPCN regions (weaker activation), which evidences greater efficiency of the executive control system. Consequently, more resources are available to process and inhibit anxiety, which might be further reflected by increased activation of the DMN regions. <bold>C</bold> MPH-driven expansion of overall resources as reflected by stronger activation of both the FPCN regions (i.e., better cognitive performance and inhibition of interference from non-relevant stimuli) and the DMN regions (i.e., processing of anxiety without interfering with cognitive performance).</p>
            </caption>
            <graphic id="d32e496" position="float" orientation="portrait" ns0:href="41398_2021_1621_Fig1_HTML.jpg" />
          </fig>
        </p>
        <p id="Par5">Finally, consistent with previous works [e.g., [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], we expected that MPH-driven effect would be detected most reliably in the task condition that requires the most resources, i.e., at the highest WM load, during induced-anxiety (compared to safety), and when the task is novel to the participants (beginning vs. later in the WM performance).</p>
      </sec>
      <sec id="Sec2" sec-type="materials|methods">
        <title>Materials and methods</title>
        <sec id="Sec3">
          <title>Participants</title>
          <p id="Par6">Seventy healthy volunteers were recruited from the Washington DC metropolitan area. Sample size was determined prior to recruitment based on our previous psychopharmacological study using MPH conducted in the clinic [<xref ref-type="bibr" rid="CR16">16</xref>]. A comprehensive clinical (medical history and exam) and psychiatric [SCID I/NP; [<xref ref-type="bibr" rid="CR26">26</xref>]] screen confirmed criteria for study participation. Inclusion criteria were: (a) age between 18 and 50 years; (b) no past or current Axis I psychiatric disorders, (c) no family history of psychiatric disorder in first-degree relatives, (d) no significant medical or neurological conditions that might interfere with participation in the study, (e) no use of psychotropic medications, tobacco, or illicit drugs (urine screen), and (f) no contraindications to magnetic resonance imaging (MRI). In addition, exclusion was based on the following criteria: (a) prior chronic use of MPH such as Ritalin, (b) intelligence quotient (IQ) &lt;80 as assessed using the vocabulary and matrix reasoning subscales of the Wechsler Abbreviated Scale of Intelligence [WASI; [<xref ref-type="bibr" rid="CR27">27</xref>]], (c) pregnancy or a positive pregnancy test. Twenty participants were excluded from analyses due to missing functional MRI (fMRI) sequences (<italic toggle="yes">n</italic> = 4), incomplete behavioral data (<italic toggle="yes">n</italic> = 6), and excessive head motion (<italic toggle="yes">n</italic> = 10). The final sample consisted of 50 healthy, right-handed adults (26 females; age mean = 28.2 years, SD = 6.9 years). Demographic information of the two groups is presented in Table <xref rid="MOESM1" ref-type="media">S1</xref>. Prior to participation, all subjects signed consent form approved by the National Institute of Mental Health Combined NeuroScience Institutional Review Board and were compensated for their time. Study procedure is detailed in Supplemental Material.</p>
        </sec>
        <sec id="Sec4">
          <title>Drug administration</title>
          <p id="Par7">A randomized double-blind parallel-group design was used in this PLA-controlled study. Participants were randomly assigned to receive either a single oral dose of PLA or immediate-release MPH 20 mg (Ritalin, Novartis, Basel, Switzerland), according to a randomization schedule established by the National Institutes of Health pharmacy. PLA and MPH oral doses were presented in identical-appearing capsules. The MPH dose was selected based on the lowest dose reported to be effective on cognitive function [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Plasma levels of MPH have been reported to peak 1–2 h after drug administration, with a plasma half-life ranging from 1 to 4 hr [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Therefore, drug was administered 90 min prior to beginning the experimental WM task in the scanner [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Potential side effects and adverse reactions were monitored using a clinician-administered 34-item Adverse Events Checklist.</p>
        </sec>
        <sec id="Sec5">
          <title>
            <italic toggle="yes">N</italic>-Back WM task</title>
          <p id="Par8">The <italic toggle="yes">N</italic>-Back WM task consisted of single letters displayed sequentially (see Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Participants were asked to press a button to indicate whether the letter currently presented on the screen was identical to (matched) or different from (did not match) the letter presented <italic toggle="yes">N</italic> letters before. Based on previous studies using the <italic toggle="yes">N</italic>-Back WM task [e.g., [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]], 33% of the letters were identical to the letter presented <italic toggle="yes">N</italic> letters before. Two levels of difficulty were tested: 1-Back and 3-Back. An instruction screen (8000 ms) appeared at the beginning of each block to signal the upcoming level of the WM load. The task was organized into two runs with Run-2 starting 10 min after Run-1. Each run consisted of 8 blocks of 18 letters each (see Supplemental Material for additional details related to stimuli and apparatus). Letters were presented for 500 ms at 2000 ms interval. In each run, blocks alternated between periods of safety (Safe blocks) and threat of unpredictable electrical shocks (Threat blocks) (see Fig. <xref rid="Fig3" ref-type="fig">3A</xref>). Each Safe and Threat block was paired with a level of difficulty (1-Back, 3-Back), so that each run contained two blocks per conditions (i.e., 1-Back/Safe, 3-Back/Safe, 1-Back/Threat, 3-Back/Threat). The color surrounding the letter presented on the screen signaled a Safe block (blue) or a Threat block (orange). Participants were instructed that they would never receive an electrical shock during the Safe blocks (blue) but that they could receive unpredictable electrical shocks at any time during the Threat blocks (orange). In total, six shocks were delivered throughout the task, three per run (see Supplemental Material for additional details related to shock intensity calibration).<fig id="Fig2" position="float" orientation="portrait">
              <label>Fig. 2</label>
              <caption>
                <title>Schematic of the <italic toggle="yes">N</italic>-Back working memory (WM) task.</title>
                <p>
                  <bold>A</bold> Illustration of the two runs, one starting with a Threat block, and the other with a Safe block. The order of runs was counterbalanced across participants. In addition, participants performed the task in two different contexts, safety (Safe blocks) or threat of electrical shock (Threat blocks). Safe and Threat blocks alternated within each run and were paired with difficulty (i.e., 1-Back or 3-Back task). Each run comprised 8 blocks (45 s each) in total, with 2 blocks per task condition (i.e., 1-Back/Safe, 1-Back/Threat, 3-Back/Safe, 3-Back/Threat). <bold>B</bold> Illustration of a Safe block (letters surrounded by blue color) of a 1-Back task and a Threat block (letters surrounded by orange color) of a 3-Back task. At the beginning of each block, an instruction screen (8000 ms) notified participants of task load, i.e., 1-Back or 3-Back task. Within each block, 18 letters were sequentially presented for 500 ms at 2000 ms interval. Prior to the experiment, participants were instructed that, during the Safe blocks (letters surrounded by blue color), they would never receive an electrical shock, whereas unpredictable electrical shocks could be delivered at any time during the Threat blocks (letters surrounded by orange color). In total, six shocks were delivered throughout the task, three in each run.</p>
              </caption>
              <graphic id="d32e618" position="float" orientation="portrait" ns0:href="41398_2021_1621_Fig2_HTML.jpg" />
            </fig>
            <fig id="Fig3" position="float" orientation="portrait">
              <label>Fig. 3</label>
              <caption>
                <title>Interaction effect of <italic toggle="yes">Drug</italic>, <italic toggle="yes">Run</italic>, and <italic toggle="yes">Condition</italic> on WM-related BOLD activation in left precuneus (PCU) and left superior parietal lobule (<italic toggle="yes">SPL</italic>).</title>
                <p>Upper panel: <italic toggle="yes">Drug</italic> by <italic toggle="yes">Run</italic> by <italic toggle="yes">Condition</italic> interaction on WM-related BOLD (3-Back vs. 1-Back contrast) recruitment of the <bold>A</bold> left PCU and <bold>B</bold> left SPL. Lower panel: Histograms of the parameter estimates extracted from the <bold>A</bold> left PCU and <bold>B</bold> left SPL. Linear mixed-effects models were conducted on the parameter estimates with <italic toggle="yes">Drug</italic>, <italic toggle="yes">Run</italic>, and <italic toggle="yes">Condition</italic> as fixed factors, and <italic toggle="yes">Subjects</italic> as random factor. <italic toggle="yes">Sex</italic> and <italic toggle="yes">Age</italic> were included as covariates. Error bars represent mean ± standard error of the mean. Color bar: warm colors represent WM-related BOLD activation in MPH compared to PLA, while cool colors represent WM-related BOLD activation decrease in MPH compared to PLA. Crosshairs depict the location of the voxel with the peak activation for the given cluster. Wholebrain activations are corrected for multiple comparisons using a cluster-based approach with a voxel-wise bi-sided <italic toggle="yes">p</italic>-value threshold of <italic toggle="yes">p</italic> &lt; 0.001 and a minimum cluster size of <italic toggle="yes">k</italic> = 16 (432 μL), which corresponds to a cluster-level alpha of <italic toggle="yes">p</italic> &lt; 0.05 using NN2 clustering, where clustered voxels can share faces and edges. For visualization purpose, whole-brain activationsare thresholded here at <italic toggle="yes">p</italic> = 0.01. *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt; 0.01, ***<italic toggle="yes">p</italic> &lt; 0.001.</p>
              </caption>
              <graphic id="d32e707" position="float" orientation="portrait" ns0:href="41398_2021_1621_Fig3_HTML.jpg" />
            </fig>
          </p>
        </sec>
        <sec id="Sec6">
          <title>Anxiety subjective ratings</title>
          <p id="Par9">Subjective anxiety was assessed from two perspectives, general anxiety state across the whole study visit and anxiety in the fMRI, specifically linked to task performance. The State-Trait Anxiety Inventory [STAI-s; [<xref ref-type="bibr" rid="CR35">35</xref>]] monitored general state anxiety at three time points: (1) STAI-s 1, right after drug administration (T1), when the pharmacological action of the drug had not yet started to take effect, (2) STAI-s 2, 45 min post drug administration. At this time, MPH was expected to start having clinical effects (T2). Finally, (3) STAI-s 3, as soon as participants were removed from the scanner (T3). Information related to anxiety assessment during fMRI are presented in Supplemental Material.</p>
        </sec>
        <sec id="Sec7">
          <title>fMRI data acquisition and analysis</title>
          <sec id="Sec8">
            <title>fMRI data acquisition</title>
            <p id="Par10">Two runs of 225 multi-echo EPI (echo planar imaging) images were collected using a 3 T Siemens MAGNETOM Skyra (Erlangen, Germany) fMRI system and a 32-channel head coil. Thirty-two interleaved 3 mm slices (matrix = 64 mm × 64 mm) were collected parallel to the anterior commissure–posterior commissure line with an anterior-to-posterior phase encoding direction (repetition time (TR) = 2000 ms; echo time (TE) = 12, 24.48, 36.96 ms; flip angle = 70°). Additionally, a multi-echo T1-weighted magnetization-prepared rapid gradient-echo (MPRAGE) image (TR = 2530 ms; TE = 1.69, 3.55, 5.41, 7.27 ms; flip angle = 7°) was acquired. T1-weighted MPRAGE images consisted of interleaved 1 mm axial slices (matrix = 256 mm × 256 mm), which were later co-registered to the combined EPI images.</p>
          </sec>
          <sec id="Sec9">
            <title>fMRI data analysis</title>
            <p id="Par11">fMRI data were analyzed using the Analysis of Functional and Neural Images (AFNI) software package [<xref ref-type="bibr" rid="CR36">36</xref>]. Multi-echo T1-weighted MPRAGE images were first optimally combined using the “<italic toggle="yes">@compute_OC_weights</italic>” program in AFNI and then processed using <italic toggle="yes">FreeSurfer</italic> (v6.0.0.) [<xref ref-type="bibr" rid="CR37">37</xref>] to obtain segmentation masks corresponding to the brain (skull-stripped), white matter, and ventricles. The “<italic toggle="yes">@SSwarper</italic>” AFNI program was used for skull-stripping and non-linear warping the combined T1-weighted MPRAGE dataset to standard space using the ICBM 2009c Nonlinear Symmetric atlas [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]. The pre-processing was performed on the EPI data using the “<italic toggle="yes">afni_proc.py”</italic> script (see Supplemental Material for additional details). In the first-level analysis, regressors of no interest were created from six motion parameters, per run, fourth-degree polynomial terms to model slow drifts, and shock onsets. Each condition comprising 1-Back/Safe, 1-Back/Threat, 3-Back/Safe, and 3-Back/Threat was entered as a regressor of interest. To determine the differential effect of high (3-Back) compared to low (1-Back) WM load on blood-oxygen-level dependent (BOLD) responses, a general linear test (GLT) was included at the first-level analysis, comparing the 3-Back WM load to the 1-Back WM load. In the second-level analysis, we first performed a general linear model (GLM) with <italic toggle="yes">Drug</italic> (MPH, PLA), <italic toggle="yes">Load</italic> (1-Back, 3-Back), <italic toggle="yes">Condition</italic> (Safe, Threat), and <italic toggle="yes">Run</italic> (Run-1, Run-2) as fixed factors and <italic toggle="yes">Subjects</italic> as random factor. <italic toggle="yes">Sex</italic> and <italic toggle="yes">Age</italic> (grand-mean centered) were added as control covariates. This preliminary second-level analysis was conducted as a quality control to assess the consistency of the main effect of WM load (3-Back vs. 1-Back) with the literature. All subsequent second-level analyses were conducted on the WM load contrast (3-Back vs. 1-Back) included as a GLT in the first-level analysis. Next, we performed a GLM with <italic toggle="yes">Drug</italic> (MPH, PLA), <italic toggle="yes">Condition</italic> (Safe, Threat), and <italic toggle="yes">Run</italic> (Run-1, Run-2) as fixed factors and <italic toggle="yes">Subjects</italic> as random factor to determine their effect on the BOLD responses contrasting the 3-Back with the 1-Back tasks. <italic toggle="yes">Sex</italic> and <italic toggle="yes">Age</italic> (grand-mean centered) were added as control covariates. To better understand this three-way interaction, we further examined the <italic toggle="yes">Drug</italic> × <italic toggle="yes">Condition</italic> interaction in Run-1 and Run-2 separately. The resulting statistical group maps were corrected for multiple comparisons using a cluster-thresholding technique. A minimum cluster size threshold was estimated based on the estimated smoothness of an average of all subjects’ spatial smoothness computed with “<italic toggle="yes">afni_proc.py”</italic> program. Given the non-Gaussian spatial distribution of noise BOLD data, we used an autoregressive function to estimate the smoothness of our fMRI data [<xref ref-type="bibr" rid="CR41">41</xref>]. A Monte Carlo simulation using the AFNI program “<italic toggle="yes">3dClustSim”</italic> determined the cluster size threshold of 16 voxels (432 μL) corresponding to corrected statistical results with a voxel-wise bi-sided threshold of <italic toggle="yes">p</italic> &lt; 0.001 and with a threshold for whole-brain multiple comparisons set at <italic toggle="yes">p</italic> &lt; 0.05 using NN2 clustering, where clustered voxels can share faces and edges. As complementary analyses, parameter estimates were further extracted from each significant cluster in the <italic toggle="yes">Drug</italic> × <italic toggle="yes">Condition</italic> interaction for Run-1 and Run-2 separately and entered into R. Linear mixed-effects (LME) models were conducted with <italic toggle="yes">Drug</italic> (MPH, PLA), <italic toggle="yes">Run</italic> (Run-1, Run-2), and <italic toggle="yes">Condition</italic> (Safe, Threat) as fixed factors, <italic toggle="yes">Subjects</italic> as random factor, and <italic toggle="yes">Sex</italic> and <italic toggle="yes">Age</italic> (grand-mean centered) included as control covariates.</p>
          </sec>
        </sec>
        <sec id="Sec10">
          <title>
            <italic toggle="yes">N</italic>-Back WM task performance data analysis</title>
          <p id="Par12">The effects of <italic toggle="yes">Drug</italic> (MPH, PLA), <italic toggle="yes">Condition</italic> (Safe, Threat), <italic toggle="yes">Load</italic> (1-Back, 3-Back), and <italic toggle="yes">Run</italic> (Run-1, Run-2) on cognitive performance (response accuracy and reaction time (RT)) were analyzed with LME using the function “lmer” of the lme4 package in R programming language [<xref ref-type="bibr" rid="CR42">42</xref>]. <italic toggle="yes">Drug</italic> (MPH, PLA), <italic toggle="yes">Condition</italic> (Safe, Threat), <italic toggle="yes">Load</italic> (1-Back, 3-Back), and <italic toggle="yes">Run</italic> (Run-1, Run-2) were included as fixed-effects factors and <italic toggle="yes">Subjects</italic> as random effect. Additionally, <italic toggle="yes">Sex</italic> and <italic toggle="yes">Age</italic> (grand-mean centered) were added as control covariates (see Supplemental Material for additional details).</p>
        </sec>
        <sec id="Sec11">
          <title>Anxiety subjective rating data analysis</title>
          <p id="Par13">General state anxiety (STAI-s) ratings were analyzed using a LME model with <italic toggle="yes">Drug</italic> (MPH, PLA) and <italic toggle="yes">Time</italic> (T1, T2, and T3) included as fixed-effects factors and <italic toggle="yes">Subjects</italic> as random effect. <italic toggle="yes">Sex</italic> and <italic toggle="yes">Age</italic> (grand-mean centered) were used as control covariates (see Supplemental Material for additional details). Data analysis of anxiety responses during fMRI is presented in Supplemental Material.</p>
        </sec>
      </sec>
      <sec id="Sec12" sec-type="results">
        <title>Results</title>
        <sec id="Sec13">
          <title>Sample characteristics</title>
          <p id="Par14">Groups (MPH, PLA) did not differ on age, IQ, weight (kg), shock intensity (mA), or retrospective ratings of shock discomfort following Run-1 and Run-2 (see Table <xref rid="MOESM1" ref-type="media">S1</xref>).</p>
        </sec>
        <sec id="Sec14">
          <title>WM performance: response accuracy and RT</title>
          <p id="Par15">Results are presented first for accuracy and then for RT (see Tables <xref rid="MOESM1" ref-type="media">S2</xref> and <xref rid="MOESM1" ref-type="media">S3</xref>).</p>
          <sec id="Sec15">
            <title>Accuracy</title>
            <p id="Par16">The omnibus 4-way (<italic toggle="yes">Drug</italic> × <italic toggle="yes">Run</italic> × <italic toggle="yes">Condition</italic> × <italic toggle="yes">Load</italic>) LME model analysis revealed a trend for the 4-way interaction (<italic toggle="yes">β</italic> = −0.11, <italic toggle="yes">t</italic>
              <sub>(350)</sub> = −1.69, <italic toggle="yes">p</italic> = 0.09), in addition to other significant main effects and interactions. Of note, <italic toggle="yes">Drug</italic> exhibited a trend for a main effect, reflecting higher accuracy in the MPH than in the PLA group (<italic toggle="yes">β</italic> = 0.05, <italic toggle="yes">t</italic>
              <sub>(323)</sub> = 1.87, <italic toggle="yes">p</italic> = 0.06). Additionally, <italic toggle="yes">Load</italic> significantly affected accuracy with lower accuracy in the 3-Back than in the 1-Back WM task (<italic toggle="yes">β</italic> = −0.17, <italic toggle="yes">t</italic>
              <sub>(350)</sub> = −7.57, <italic toggle="yes">p</italic> &lt; 0.001) (see Supplemental Material for results related to the decomposition of the 4-way interaction by run).</p>
          </sec>
          <sec id="Sec16">
            <title>Reaction time</title>
            <p id="Par17">The omnibus 4-way (<italic toggle="yes">Drug</italic> × <italic toggle="yes">Run</italic> × <italic toggle="yes">Condition</italic> × <italic toggle="yes">Load</italic>) LME model analysis revealed the main effect of <italic toggle="yes">Load</italic> to be statistically significant and the main effect of <italic toggle="yes">Run</italic> to emerge at a trend level. RTs were faster in Run-2 than in Run-1 (<italic toggle="yes">β</italic> = −60.54, <italic toggle="yes">t</italic>
              <sub>(350)</sub> = −1.79, <italic toggle="yes">p</italic> = 0.07) and in the 1-Back than in the 3-Back WM task (<italic toggle="yes">β</italic> = −223.41, <italic toggle="yes">t</italic>
              <sub>(350)</sub> = −6.59, <italic toggle="yes">p</italic> &lt; 0.001). No other significant effects were found.</p>
          </sec>
        </sec>
        <sec id="Sec17">
          <title>fMRI analysis: whole-brain activation maps</title>
          <sec id="Sec18">
            <title>Main effect of working-memory load (3-Back vs. 1-Back)—quality-control step</title>
            <p id="Par18">As a quality control to validate the activation pattern of WM, a whole-brain GLM analysis was conducted with <italic toggle="yes">Drug</italic>, <italic toggle="yes">Run</italic>, <italic toggle="yes">Condition</italic>, and <italic toggle="yes">Load</italic> as fixed factors (see Table <xref rid="MOESM1" ref-type="media">S4</xref>). As expected, the WM-load (3-Back vs. 1-Back) contrast engaged task-positive networks and disengaged the task-negative network (see Fig. <xref rid="MOESM1" ref-type="media">S1</xref> and additional details in Supplemental Material). All subsequent analyses were conducted on the WM load contrast (3-Back vs. 1-Back).</p>
          </sec>
          <sec id="Sec19">
            <title>GLM in whole-brain analysis: <italic toggle="yes">Drug</italic> × <italic toggle="yes">Run</italic> × <italic toggle="yes">Condition</italic> interaction</title>
            <sec id="FPar1">
              <title>
                <italic toggle="yes">Drug</italic> × <italic toggle="yes">Run</italic> × <italic toggle="yes">Condition</italic> interaction</title>
              <p id="Par19">At the threshold of <italic toggle="yes">p</italic>
                <sub>uncorrected</sub> &lt; 0.01, three clusters reached significance (for a minimal number of voxels equal to <italic toggle="yes">k</italic> = 20). These clusters included regions in the superior parietal lobule (SPL) and the posterior cingulate cortex (PCC)/precuneus (PCU), as well as in the inferior temporal gyrus.</p>
            </sec>
            <sec id="FPar2">
              <title>
                <italic toggle="yes">Drug</italic> × <italic toggle="yes">Condition</italic> interaction in Run-1 and Run-2 separately</title>
              <p id="Par20">
                <italic toggle="yes">Run-1</italic>: <italic toggle="yes">Drug</italic> × <italic toggle="yes">Condition</italic> interaction: At the whole-brain level, five clusters were significant in Run-1 after cluster-wise correction for multiple comparisons (see Table <xref rid="Tab1" ref-type="table">1</xref>). These clusters were located in the parietal/cingulate cortex (left PCU, right PCC, left SPL), prefrontal cortex (right lateral orbitofrontal cortex (lOFC)), and occipital cortex (left lateral occipital cortex (lOC)). This two-way interaction map was decomposed by <italic toggle="yes">Condition</italic>. During Threat, all five clusters were more activated in the MPH group than in the PLA group. During Safe, no clusters significantly differed between the MPH and PLA groups.<table-wrap id="Tab1" position="float" orientation="portrait">
                  <label>Table 1</label>
                  <caption>
                    <p>Significant interaction clusters between <italic toggle="yes">Drug</italic> (MPH, PLA) and <italic toggle="yes">Condition</italic> (Safe, Threat) on WM load-related BOLD (3-Back vs. 1-Back) activation in Run-1.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th colspan="1" rowspan="1">Label</th>
                        <th colspan="1" rowspan="1">Brodmann area</th>
                        <th colspan="1" rowspan="1">Side</th>
                        <th colspan="3" rowspan="1">Peak activation</th>
                        <th colspan="1" rowspan="1">Number of voxels</th>
                        <th colspan="1" rowspan="1">Volume (μL)</th>
                        <th colspan="1" rowspan="1">Mean</th>
                        <th colspan="1" rowspan="1">SEM</th>
                        <th colspan="1" rowspan="1">
                          <italic toggle="yes">t</italic> value</th>
                      </tr>
                      <tr>
                        <th colspan="1" rowspan="1" />
                        <th colspan="1" rowspan="1" />
                        <th colspan="1" rowspan="1" />
                        <th colspan="1" rowspan="1">
                          <italic toggle="yes">x</italic>
                        </th>
                        <th colspan="1" rowspan="1">
                          <italic toggle="yes">y</italic>
                        </th>
                        <th colspan="1" rowspan="1">
                          <italic toggle="yes">z</italic>
                        </th>
                        <th colspan="1" rowspan="1" />
                        <th colspan="1" rowspan="1" />
                        <th colspan="1" rowspan="1" />
                        <th colspan="1" rowspan="1" />
                        <th colspan="1" rowspan="1" />
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="11" rowspan="1">Drug × Condition in Run-1: MPH vs. PLA in Threat condition</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1"> Precuneus</td>
                        <td colspan="1" rowspan="1">31</td>
                        <td colspan="1" rowspan="1">L</td>
                        <td colspan="1" rowspan="1">−11</td>
                        <td colspan="1" rowspan="1">−50</td>
                        <td colspan="1" rowspan="1">38</td>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">621</td>
                        <td colspan="1" rowspan="1">4367</td>
                        <td colspan="1" rowspan="1">184</td>
                        <td colspan="1" rowspan="1">3.65</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1"> Posterior cingulate cortex</td>
                        <td colspan="1" rowspan="1">31</td>
                        <td colspan="1" rowspan="1">R</td>
                        <td colspan="1" rowspan="1"> 5</td>
                        <td colspan="1" rowspan="1">−23</td>
                        <td colspan="1" rowspan="1">44</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">594</td>
                        <td colspan="1" rowspan="1">3831</td>
                        <td colspan="1" rowspan="1">162</td>
                        <td colspan="1" rowspan="1">4.33</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1"> Superior parietal</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">L</td>
                        <td colspan="1" rowspan="1">−17</td>
                        <td colspan="1" rowspan="1">−80</td>
                        <td colspan="1" rowspan="1">56</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">567</td>
                        <td colspan="1" rowspan="1">7910</td>
                        <td colspan="1" rowspan="1">709</td>
                        <td colspan="1" rowspan="1">3.51</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1"> Lateral occipital</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">L</td>
                        <td colspan="1" rowspan="1">−20</td>
                        <td colspan="1" rowspan="1">−104</td>
                        <td colspan="1" rowspan="1">−5</td>
                        <td colspan="1" rowspan="1">20</td>
                        <td colspan="1" rowspan="1">540</td>
                        <td colspan="1" rowspan="1">3652</td>
                        <td colspan="1" rowspan="1">253</td>
                        <td colspan="1" rowspan="1">3.54</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1"> Lateral orbitofrontal</td>
                        <td colspan="1" rowspan="1">47</td>
                        <td colspan="1" rowspan="1">R</td>
                        <td colspan="1" rowspan="1">35</td>
                        <td colspan="1" rowspan="1">38</td>
                        <td colspan="1" rowspan="1">−17</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">432</td>
                        <td colspan="1" rowspan="1">4452</td>
                        <td colspan="1" rowspan="1">275</td>
                        <td colspan="1" rowspan="1">4.31</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Degrees of freedom equal 46. Whole-brain activations are corrected for multiple comparisons using a cluster-based approach with a voxel-wise bi-sided <italic toggle="yes">p</italic> value threshold of <italic toggle="yes">p</italic> &lt; 0.001 and a minimum cluster size of <italic toggle="yes">k</italic> = 16 (432 μL), which corresponds to a cluster-level alpha of <italic toggle="yes">p</italic> &lt; 0.05 using NN2 clustering, where clustered voxels can share faces and edges. LPI means that <italic toggle="yes">x</italic> increases from Left to Right, <italic toggle="yes">y</italic> increases from Posterior to Anterior, <italic toggle="yes">z</italic> increases from Inferior to Superior; Mean and standard error of the mean (SEM) based on absolute value of voxel intensities; correspondences with Brodmann areas are retrieved from the Yale University BioImage Suite.</p>
                    <p>
                      <italic toggle="yes">L</italic> left, <italic toggle="yes">R</italic> right.</p>
                  </table-wrap-foot>
                </table-wrap>
              </p>
              <p id="Par21">
                <italic toggle="yes">Run-2</italic>: <italic toggle="yes">Drug</italic> × <italic toggle="yes">Condition</italic> interaction: In Run-2, the <italic toggle="yes">Drug</italic> × <italic toggle="yes">Condition</italic> interaction did not reveal any statistically significant clusters.</p>
            </sec>
          </sec>
          <sec id="Sec20">
            <title>
              <italic toggle="yes">Drug</italic> × <italic toggle="yes">Run</italic> × <italic toggle="yes">Condition</italic> interaction on extracted parameter estimates (3-Back vs. 1-Back contrast)</title>
            <p id="Par22">As a reminder, all extracted parameter estimates correspond to the WM load contrast (3-Back vs. 1-Back). Results are illustrated in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. As expected, the 3-way <italic toggle="yes">Drug</italic> × <italic toggle="yes">Run</italic> × <italic toggle="yes">Condition</italic> interaction was significant for all clusters. Four of the five clusters exhibited the same pattern of effects. These four clusters included the PCU, PCC, lOC, and lOFC. Figure <xref rid="Fig3" ref-type="fig">3A</xref> presents this common pattern using the PCU as the exemplar (see Fig. S2 for the illustration pattern of lOC and lOFC, and Fig. S3 for PCC). The fifth distinct cluster is the SPL whose pattern is illustrated in Fig. <xref rid="Fig3" ref-type="fig">3B</xref>.</p>
            <sec id="FPar3">
              <title>Post hoc analyses of the PCU cluster</title>
              <p id="Par23">The pattern discussed below for the PCU was similar for the other three clusters.</p>
              <p id="Par24">
                <italic toggle="yes">Run-1</italic>: In Run-1, the PLA group exhibited a significant deactivation to <italic toggle="yes">Load</italic> during Threat (<italic toggle="yes">β</italic> = −0.26, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = −4.40, <italic toggle="yes">p</italic> &lt; 0.001) and a non-significant activation to <italic toggle="yes">Load</italic> during Safe (<italic toggle="yes">β</italic> = 0.06, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 1.10, <italic toggle="yes">p</italic> = 0.55). In contrast, the MPH group showed no significant WM-related changes of the PCU responses in either Threat (<italic toggle="yes">β</italic> = 0.09, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 1.55, <italic toggle="yes">p</italic> = 0.49) or Safe (<italic toggle="yes">β</italic> = −0.01, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = −0.12, <italic toggle="yes">p</italic> = 0.90). In other words, in Run-1, the PLA group responded to Threat with a significant deactivation of this cluster compared to the MPH group.</p>
              <p id="Par25">
                <italic toggle="yes">Run-2</italic>: In Run-2, the PLA group exhibited a significant deactivation of the PCU cluster to <italic toggle="yes">Load</italic> during Safe (<italic toggle="yes">β</italic> = −0.16, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = −2.72, <italic toggle="yes">p</italic> = 0.03) and an even steeper deactivation during Threat (<italic toggle="yes">β</italic> = −0.26, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = −4.32, <italic toggle="yes">p</italic> &lt; 0.001). The MPH group showed a similar, but weaker, pattern. Particularly, the deactivation of the PCU during Safe was not significant (<italic toggle="yes">β</italic> = −0.08, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = −1.43, <italic toggle="yes">p</italic> = 0.49), while it was significant during Threat (<italic toggle="yes">β</italic> = −0.17, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = −2.89, <italic toggle="yes">p</italic> = 0.02). In other words, in Run-2, <italic toggle="yes">Load</italic> tended to deactivate the PCU in both the PLA and MPH groups and in both Safe and Threat.</p>
              <p id="Par26">Overall, in contrast to Run-1, in Run-2 <italic toggle="yes">Threat</italic> modulated the PCU response to <italic toggle="yes">Load</italic> in both the MPH and PLA groups in a similar way (see Fig. <xref rid="Fig3" ref-type="fig">3A</xref>).</p>
            </sec>
            <sec id="FPar4">
              <title>Post hoc analyses of the SPL cluster</title>
              <p id="Par27">
                <italic toggle="yes">Run-1</italic>: in Run-1, the PLA group exhibited a significant activation to <italic toggle="yes">Load</italic> during Safe (<italic toggle="yes">β</italic> = 0.33, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 3.39, <italic toggle="yes">p</italic> &lt; 0.001) but no significant effect during Threat (<italic toggle="yes">β</italic> = −0.09, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = −0.97, <italic toggle="yes">p</italic> = 0.33). In contrast, the MPH group showed increased activation to <italic toggle="yes">Load</italic> during Safe (<italic toggle="yes">β</italic> = 0.22, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 2.28, <italic toggle="yes">p</italic> = 0.07) and even stronger during Threat (<italic toggle="yes">β</italic> = 0.52, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 5.38, <italic toggle="yes">p</italic> &lt; 0.001). In other words, in Run-1, the activation effect of <italic toggle="yes">Load</italic> during Safe was no longer present during Threat in the PLA group. In contrast, the activation effect of <italic toggle="yes">Load</italic> seen during Safe was potentiated during Threat in the MPH group as well as significantly higher than in the PLA group (see Fig. <xref rid="Fig3" ref-type="fig">3B</xref>).</p>
              <p id="Par28">
                <italic toggle="yes">Run-2</italic>: In Run-2, the PLA group exhibited no significant SPL activation to <italic toggle="yes">Load</italic> during <italic toggle="yes">Safe</italic> (<italic toggle="yes">β</italic> = 0.14, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 1.43, <italic toggle="yes">p</italic> = 0.31), while the activation of the SPL cluster to <italic toggle="yes">Load</italic> was significantly increased during Threat (<italic toggle="yes">β</italic> = 0.26, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 2.66, <italic toggle="yes">p</italic> = 0.03). In contrast, the MPH group showed a significant increase of the SPL activation to <italic toggle="yes">Load</italic> during Safe (<italic toggle="yes">β</italic> = 0.37, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 3.82, <italic toggle="yes">p</italic> &lt; 0.001), which was even stronger during Threat (<italic toggle="yes">β</italic> = 0.43, <italic toggle="yes">t</italic>
                <sub>(365)</sub> = 4.47, <italic toggle="yes">p</italic> &lt; 0.001). In other words, in Run-2, the SPL in response to <italic toggle="yes">Load</italic> tended to be activated with PLA, particularly during Threat, while with MPH, the SPL significantly responded to <italic toggle="yes">Load</italic> during both Safe and Threat, with stronger effect during Threat.</p>
            </sec>
          </sec>
        </sec>
        <sec id="Sec21">
          <title>Anxiety subjective ratings: general state anxiety (STAI-s)</title>
          <p id="Par29">The LME model with <italic toggle="yes">Drug</italic> and <italic toggle="yes">Time</italic> (T1, T2, T3) as fixed factors showed a significant main effect for <italic toggle="yes">Time</italic> reflecting a significant increase in anxiety from T1 to T3 (<italic toggle="yes">β</italic> = 4.21, <italic toggle="yes">t</italic>
            <sub>(98)</sub> = 4.26, <italic toggle="yes">p</italic> &lt; 0.001), a trend for <italic toggle="yes">Drug</italic> × <italic toggle="yes">Time</italic> [T2 vs. T1] interaction (<italic toggle="yes">β</italic> = 2.62, <italic toggle="yes">t</italic>
            <sub>(98)</sub> = 1.90, <italic toggle="yes">p</italic> = 0.06), and a significant <italic toggle="yes">Drug</italic> × <italic toggle="yes">Time</italic> [T3 vs. T1] interaction (<italic toggle="yes">β</italic> = 3.40, <italic toggle="yes">t</italic>
            <sub>(98)</sub> = 2.45, <italic toggle="yes">p</italic> = 0.02). The main effect of <italic toggle="yes">Time</italic> consisted of a progressive increase in STAI-s scores from T1 to T3. Participants were at the highest level of anxiety at the end of the study visit. The <italic toggle="yes">Drug</italic> × <italic toggle="yes">Time</italic> interaction reflected a steeper increase in STAI-s scores in the MPH group than in the PLA group (see Table S5 and Fig. S4). However, the mean STAI-s scores over the three time points did not differ between the MPH and PLA groups (<italic toggle="yes">β</italic> = 1.76, <italic toggle="yes">t</italic>
            <sub>(74)</sub> = 0.95, <italic toggle="yes">p</italic> = 0.35). Results related to anxiety responses during fMRI are presented in Supplemental Material (see Tables A and B).</p>
        </sec>
      </sec>
      <sec id="Sec22" sec-type="discussion">
        <title>Discussion</title>
        <p id="Par30">Interactions between anxiety and cognitive function are well documented, both at the neural and behavioral level. Neuroimaging studies consistently report a distinct engagement of the networks supporting cognitive function and self-referential processes in anxiety [[<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], for reviews, see [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]]. However, the pattern of these anxiety-related effects varies, depending on the types of data (e.g., resting state, emotional task-based, cognitive task-based fMRI). Behavioral studies strongly support a central role of WM in anxiety processes [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Although the most commonly reported association describes a disruptive effect of anxiety on cognition [e.g., [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]], a promising interaction for treatment rests on the inhibiting effect of cognitive engagement on anxiety [e.g., [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR10">10</xref>]]. Little is known of the neural mechanisms underlying this phenomenon. The present study aimed at examining the neural correlates underpinning the interaction between anxiety and cognition, extending previous behavioral findings to brain function [<xref ref-type="bibr" rid="CR16">16</xref>]. For this purpose, cognitive function was manipulated pharmacologically, while anxiety was induced by threat of shock during a WM task.</p>
        <p id="Par31">Three alternate hypotheses were tested regarding the neural systems engaged in the effect of MPH on anxiety-by-cognition interactions: (A) <italic toggle="yes">Increased functional dissociation between the FPCN and the DMN</italic> [for a review, see [<xref ref-type="bibr" rid="CR20">20</xref>]] as reflected by stronger activation of FPCN regions (task-positive network), which favors cognitive performance, and steeper deactivation of DMN regions (task-negative networks), which prevents interference from irrelevant stimuli. (B) <italic toggle="yes">Redistribution of cognitive resources</italic> as indicated by resource allocation switch from the FPCN to the DMN. This resource reallocation underlies MPH-related increased cognitive efficiency (i.e., less FPCN activation required) [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], and DMN increased engagement to process and modulate anxiety (i.e., DMN activation). (C) <italic toggle="yes">Expansion of overall resources</italic> [<xref ref-type="bibr" rid="CR16">16</xref>] as reflected by the reinforcement of both FPCN and DMN recruitment. Stronger FPCN activation enhances cognitive performance while inhibiting interference from non-relevant stimuli. Activation of the DMN serves to process anxiety [<xref ref-type="bibr" rid="CR16">16</xref>]. Our findings align with the third prediction, expansion of overall resources. In line with previous reports [e.g., [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]], we also expected the MPH-related effects to be maximal in the most challenging task condition, i.e., during induced-anxiety (Threat condition), novelty (Run-1), and high cognitive difficulty (3-Back). Findings were consistent with this prediction.</p>
        <p id="Par32">Before discussing the neural findings, it is important to verify the successful implementation of the four manipulations (i.e., <italic toggle="yes">Condition</italic>, <italic toggle="yes">Load</italic>, <italic toggle="yes">Run</italic>, and <italic toggle="yes">Drug</italic>). First, performance (RT and accuracy) was significantly reduced in the 3-Back compared to the 1-Back WM task, and brain activation pattern in response to WM was consistent with literature reports [for reviews, see [<xref ref-type="bibr" rid="CR45">45</xref>–<xref ref-type="bibr" rid="CR47">47</xref>]]. Second, RT was slower (task more difficult) in Run-1, when the task was novel, than in Run-2. Third, MPH improved cognitive performance (accuracy) across all task conditions compared to PLA.</p>
        <p id="Par33">We first address the neural effects of MPH (vs. PLA) in Run-1, the critical period for the effect of MPH. As a reminder, all fMRI analyses were conducted on the WM load contrast (3-Back vs. 1-Back) to reflect WM-related BOLD activation. This contrast specifically captured the WM process by minimizing the basic sensory-motor information processing that is common to both the 1-Back and 3-Back tasks.</p>
        <p id="Par34">In Run-1, five clusters behaved differently during <italic toggle="yes">threat</italic> and <italic toggle="yes">safety</italic> in function of <italic toggle="yes">Drug</italic> (<italic toggle="yes">Drug</italic> × <italic toggle="yes">Condition</italic> interaction in MPH vs. PLA). These clusters mapped to the posterior node of the FPCN (SPL), the DMN (PCU, PCC, lOFC), and the primary visual cortex (lOC). For clarity, we use the term FPCN in reference to the role of the SPL cluster and DMN in reference to the role of the PCU, PCC, and lOFC clusters, all three clusters exhibiting the same response pattern.</p>
        <p id="Par35">Overall, during the Run-1/Safe condition, findings did not differ between the MPH and PLA groups. It is only during the threat condition (Run-1/Threat) that MPH impacted neural responses to WM differently than PLA. During <italic toggle="yes">safety</italic>, FPCN was significantly activated, while DMN was not significantly affected. During <italic toggle="yes">threat</italic>, FPCN was significantly activated in the MPH group but showed no significant response in the PLA group. Concomitantly, DMN was significantly activated in the MPH group but was deactivated in the PLA group. These findings suggest that, during <italic toggle="yes">threat</italic>, MPH facilitated the recruitment of the FPCN and also maintained the engagement of the DMN, allowing both systems to function at a higher level compared to PLA. This pattern can be interpreted as an overall MPH-related increase of processing resources, allowing both cognitive task and anxiety to be optimally processed. In other words, while performing the task, individuals continue to be aware of potential threat and keep the capacity to appropriately respond to danger.</p>
        <p id="Par36">The behavioral and self-reported data tend to support this interpretation. Accordingly, general state anxiety self-reported in real-time throughout the study visit using the STAI-s instrument showed a steeper increase in anxiety (from Time-1 to Time-3) in the MPH group compared to the PLA group. This result is consistent with a facilitation of anxiety processing that might be conceived as internally directed cognition (e.g., worrisome thoughts) or self-referential processing elicited by the anxiety-provoking environment [for reviews, see [<xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR50">50</xref>]]. Performance accuracy was overall better in the MPH than in the PLA group, suggesting that the disproportionate increase in anxiety in the MPH compared to that in the PLA group did not affect the processing of WM. Finally, the formulation of the hypothesis of the expandability of processing resources was born out of our previous behavioral study [<xref ref-type="bibr" rid="CR16">16</xref>]. In line with the present study, our previous study showed an MPH-related 3-Back performance improvement under <italic toggle="yes">threat</italic>, accompanied by an increase in anxiety-potentiated startle, an objective measure of anxiety.</p>
        <p id="Par37">We now address findings of Run-2. In Run-2, the task and task conditions had become familiar to the participants. In this context, MPH and PLA did not differ on either neural or behavioral measures. The general pattern reflects activation of the FPCN and deactivation or no change of the DMN activity. However, it is interesting to note that, upon inspection of Fig. <xref rid="Fig3" ref-type="fig">3</xref>, SPL activation tends to be stronger in MPH than in PLA, during both <italic toggle="yes">safety</italic> and <italic toggle="yes">threat</italic>. Conversely, DMN deactivation tends to be weaker in MPH than in PLA, again during both <italic toggle="yes">safety</italic> and <italic toggle="yes">threat</italic>. Although not statistically different, these patterns would align with the notion of MPH facilitating FPCN engagement and releasing the inhibition of the DMN. To test this possibility, the study power would need to be strengthened by raising the sample size, the number of trials, and the MPH dose. Indeed, we selected the MPH PO of 20 mg dose based on experimental studies successfully using this dose [e.g., [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]] and on clinical experience with adult patients treated for attention-deficit hyperactivity disorder [e.g., [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR53">53</xref>].</p>
        <p id="Par38">The notion of resources expansibility is important because it is in contrast to the widely accepted concept of limited resources. Accordingly, the idea of limited resources is at the core of the most widely held theoretical accounts of the mechanisms underlying the interaction of anxiety with cognitive activity [<xref ref-type="bibr" rid="CR12">12</xref>]. Our findings challenge this proposition and, in turn, may bring into light some alternate mechanisms that can be exploited for optimizing or developing new therapeutic strategies. The possibility of expansibility of cognitive resources leads to the idea of cultivating the allocation of additional resources for the regulation of excessive anxiety.</p>
        <p id="Par39">This study is not without limitations. First, we did not observe the same pattern of behavioral performance reported in our previous psychopharmacological study. While our previous behavioral findings showed that enhanced cognitive function using MPH had a protective effect against anxiety at the highest load only, our present findings suggest that MPH might enhance cognitive function more globally, that is irrespective of induced-anxiety or WM load. Several factors might account for the differences between studies. Behavioral findings often do not replicate in the MRI environment compared to the clinic. Many contextual aspects differ between the two settings, including performing the task in a supine position, reduced peripheral vision, stress induced by the MRI environment, or MRI noise [for a review, see [<xref ref-type="bibr" rid="CR54">54</xref>], see also [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]]. In addition, the physiological responses to induced-anxiety using anxiety-potentiated startle reflex could not be collected in the current work. However, the present neural findings support the theory suggested by our previous clinical study according to which boosting cognition using MPH might expand processing resources. The present findings need to be replicated and additional probes of anxiety should be obtained to better characterize the effects of MPH on behavioral aspects of anxiety (e.g., reframing, avoidance). Such data would provide important information to refine interpretation of the neural findings. Second, self-reported ratings of anxiety during the <italic toggle="yes">N</italic>-Back task did not show any drug effects (see Supplemental Material), unlike the MPH-driven potentiation of anxiety assessed by the startle reflex in our previous psychopharmacological study. Even after accounting for the differences in experimental contexts (clinic vs. scanner), the discrepancy of the MPH-driven effects on the physiological (startle reflex in the behavioral study) and on the self-reported anxiety responses (Likert scales in the current study) is not surprising. These two types of responses reflect the function of two separate biological systems, which may be differently sensitive to MPH. Furthermore, the ratings of anxiety may reflect the “stress” induced by both threat of shock and the performance of a difficult task. This combination of two stressful conditions makes it difficult to clearly interpret these self-report measures. Finally, the retrospective evaluation of anxiety is subject to recollection, which introduces measurement errors. Online monitoring of anxiety in the MRI environment, which have their own drawback (e.g., interference with task performance), could be considered in future studies. Third, no venous blood was drawn to quantify plasma concentrations of MPH throughout the study visit. Therefore, we were not able to determine whether plasma drug concentration significantly differed between participants and whether the differential drug effects between Run-1 and Run-2 was dependent on plasma drug concentration. Fourth, while MPH is a reliable experimental tool, treatment of anxiety with stimulants is not indicated. Therefore, it would be important to explore other interventions that could stretch cognitive resources. Fifth, and most importantly, the present findings stand as proof of concept and need to be tested in clinical anxiety. In conclusion, findings of this study support the theory that processing resources are expandable. This is suggested by MPH-related facilitation of the FPCN and DMN recruitment, which underlies, respectively, higher level of cognitive performance and threat processing. The fuller processing of anxiety conceivably permits better regulation of anxiety so as not to interfere with other tasks. Specifically, resources would be sufficient to prevent threat stimuli from interfering with ongoing behavior and, critically, would also permit to respond appropriately to the sudden emergence of danger while being engaged in a complex cognitive activity. The possibility of expanding the limits of processing resources, here pharmacologically, might open new directions for devising interventions to treat anxiety.</p>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supplementary information</title>
        <sec id="Sec23">
          <p>
            <supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait">
              <media ns0:href="41398_2021_1621_MOESM1_ESM.docx" position="float" orientation="portrait">
                <caption>
                  <p>Supplemental Material</p>
                </caption>
              </media>
            </supplementary-material>
          </p>
        </sec>
      </sec>
    </body>
  </article>
</pmc-articleset>